Herpes simplex virus encephalitis represents one of the most critical central nervous system infections encountered in hospital practice. Intravenous acyclovir remains the cornerstone of medical management, yet patients frequently suffer severe neurological deficits and unacceptable mortality rates. Clinicians frequently encounter secondary neuroinflammation, which damages adjacent brain parenchyma during active viral clearance. Because of this destructive immune response, neurointensivists have actively explored the routine use of corticosteroids in HSV encephalitis. However, clinical evidence supporting this adjunctive intervention has remained conflicting across observational studies and small trials. A nationwide study provides crucial real-world insights into whether adding systemic steroids to early antiviral therapy truly improves patient survival or recovery.

Pathophysiological Rationale for Corticosteroids in HSV Encephalitis

Herpes simplex virus type 1 causes intense viral replication within the temporal and frontal lobes of the human brain. This biological process triggers rapid cellular lysis alongside a hyperactive host immune reaction. Cytotoxic T-lymphocytes and inflammatory cytokines invade brain tissue, generating profound cerebral edema and elevated intracranial pressure. Consequently, severe inflammation frequently exacerbates focal necrosis long after antiviral agents suppress viral replication. Clinicians frequently worry that post-infectious immunopathology causes ongoing cognitive injury and persistent functional dependency. Therefore, administering glucocorticoids appears physiologically sound because these agents mitigate vasogenic edema and downregulate dangerous inflammatory cascades. In theory, dampening excessive neuroinflammation preserves viable neuronal networks and reduces long-term neurological sequelae. Nevertheless, suppressing host immunity raises genuine clinical safety concerns. Corticosteroids might impair viral clearance, promote recurrent viral rebound, or increase vulnerability to secondary nosocomial infections. Because of these competing physiological mechanisms, physicians require rigorous clinical data before adopting routine adjunctive steroid regimens during acute viral encephalitis admissions.

Nationwide Cohort Study Design and Patient Selection

To address this therapeutic dilemma, researchers analyzed nationwide inpatient data from the Japanese Diagnosis Procedure Combination database. The investigation evaluated 3,933 adult patients hospitalized with herpes simplex encephalitis who initiated intravenous acyclovir within two days of hospital admission. Investigators divided these individuals into two distinct comparative groups based on their early medical interventions. The intervention cohort comprised 1,385 individuals who received intravenous corticosteroids at a daily prednisolone-equivalent dose of at least 30 mg within the initial 48 hours. Conversely, the control cohort included 2,548 patients treated with acyclovir alone. To ensure reliable comparisons, the investigators utilized multivariable regression models adjusted for age, baseline neurological status, comorbidities, and initial physiological severity. The primary endpoint assessed in-hospital mortality across both arms. Meanwhile, secondary outcomes evaluated functional recovery, including discharge alive with full consciousness and discharge alive with functional independence. Furthermore, the investigators tracked overall hospital length of stay and total inpatient financial costs to evaluate broader healthcare system impacts.

In-Hospital Mortality and Neurological Recovery Findings

The statistical analysis revealed that early adjunctive corticosteroid therapy failed to confer significant clinical benefits in acute encephalitis. Specifically, the adjusted in-hospital mortality was 4.2% in the combination therapy group compared to 3.2% in the acyclovir-alone group. This 1.0% absolute difference demonstrated no statistically significant survival advantage for patients receiving systemic steroids. Similarly, measures of acute neurological recovery showed nearly identical success rates across both treatment cohorts. Approximately 75.3% of steroid-treated patients achieved discharge with full consciousness compared to 75.0% of patients who received acyclovir monotherapy. Moreover, functional independence at discharge reached 62.7% in the steroid cohort versus 61.9% in the monotherapy group. Neither functional outcome reached statistical significance after robust baseline adjustments. Consequently, routine early glucocorticoid administration provided no observable improvement in survival or neurological function. These empirical findings challenge long-standing assumptions that immunosuppression routinely rescues threatened neurological tissue during the acute phase of herpes simplex encephalitis.

Resource Utilization and Inpatient Healthcare Costs

While adjunctive corticosteroids failed to enhance clinical recovery, they produced notable differences in hospital utilization and medical resource consumption. Patients receiving combined acyclovir and corticosteroid therapy experienced a significantly prolonged duration of hospitalization. The adjusted length of hospital stay averaged 35.5 days in the combination cohort compared with 29.6 days in the acyclovir-alone cohort. This difference of nearly six additional inpatient days imposed considerable burdens on families and hospital facilities. Additionally, adjusted total hospitalization costs rose sharply in the steroid cohort, averaging $14,704 compared to $12,174 among patients receiving antiviral monotherapy. This adjusted financial difference of $2,530 per patient represents a substantial escalation in acute care expenditure. Extended stays and higher treatment costs likely reflect ongoing monitoring requirements, secondary adverse events, metabolic disturbances, or slower rehabilitation trajectories. Therefore, early steroid use in unselected encephalitis patients increases economic strain without delivering measurable clinical gains.

Reconciling Observational Findings With Clinical Trial Evidence

These large-scale observational findings align remarkably well with modern prospective data from international randomized trials. For instance, the multi-center DexEnceph clinical trial investigated adjunctive dexamethasone alongside standard acyclovir therapy in adult herpes simplex encephalitis. That prospective trial observed no significant improvement in long-term verbal memory scores at 26 weeks. However, clinical investigators have noted that early administration of steroids in undifferentiated encephalitis appears relatively safe while clinicians await confirmatory diagnostics. This nuance carries immense clinical relevance because autoimmune encephalitis frequently mimics viral encephalitis during early emergency presentation. In cases where intracranial hypertension or massive focal edema causes impending brain herniation, targeted corticosteroid administration remains an indispensable neurocritical intervention. Nevertheless, applying high-dose corticosteroids routinely to every confirmed viral encephalitis patient remains unsupported by contemporary literature. Clinicians must distinguish between targeted life-saving rescue therapy for mass effect and unselected routine immunosuppression.

Clinical Implications for Practice in Resource-Conscious Settings

Physicians managing acute encephalopathy must maintain prompt administration of intravenous acyclovir as the non-negotiable priority. When adult patients present with acute fever, confusion, and focal neurological signs, immediate antiviral dosing prevents irreversible neuronal death. Clinicians should not delay acyclovir while awaiting lumbar puncture or neuroimaging. Concurrently, medical teams should avoid routine high-dose corticosteroid therapy in confirmed herpes simplex encephalitis cases lacking intracranial hypertension. Instead, physicians should reserve systemic corticosteroids for specific secondary complications, such as impending uncal herniation, refractory mass effect, or subsequent autoimmune post-infectious encephalitis. Regular neurological monitoring, blood glucose management, and early neurorehabilitation yield superior therapeutic dividends compared to indiscriminate anti-inflammatory regimens. Future clinical research must pinpoint precise patient subsets that might genuinely benefit from targeted anti-inflammatory regimens. Until such biomarkers and stratified clinical trials emerge, antiviral monotherapy remains the optimal, evidence-based standard of care for herpes simplex encephalitis.

Frequently Asked Questions

Should clinicians routinely prescribe corticosteroids in HSV encephalitis?

Current clinical evidence does not support the routine administration of corticosteroids in patients with herpes simplex encephalitis. Large cohort studies show no reduction in in-hospital mortality or improvement in functional recovery. Clinicians should reserve corticosteroids for severe secondary complications, such as impending brain herniation or marked cerebral mass effect.

What did the nationwide cohort study reveal regarding hospital stay?

The nationwide retrospective study revealed that patients receiving adjunctive corticosteroids experienced significantly longer hospital stays, averaging nearly six additional days compared to antiviral monotherapy. Furthermore, total hospitalization costs were substantially higher in the steroid cohort, demonstrating an increased healthcare burden without corresponding improvements in functional neurological recovery.

Is early corticosteroid administration safe when encephalitis etiology remains uncertain?

Prospective studies indicate that short-term corticosteroids carry an acceptable safety profile when clinicians evaluate suspected acute encephalitis before confirming a viral or autoimmune etiology. However, once diagnostic tests confirm herpes simplex virus infection, physicians should avoid routine high-dose steroids unless specific indications like refractory intracranial pressure arise.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

Shinmoto K et al. In-Hospital Outcomes of Acyclovir With or Without Corticosteroid for Herpes Simplex Encephalitis: A Nationwide Retrospective Cohort Study. Neurol Clin Pract. 2026 Dec. doi: 10.1212/CPJ.0000000000200675. PMID: 42913452.

Solomon T, Michael BD, Smith PE, et al. Management of Suspected Viral Encephalitis in Adults: Association of British Neurologists and British Infection Association National Guidelines. J Infect. 2012;64(4):347-373.

DexEnceph Study Collaborative Group. Dexamethasone in Herpes Simplex Virus Encephalitis: A Multicentre Randomised Controlled Trial. Lancet Neurol. 2026;25(2):145-156.